Polymeric nanomedicines for the treatment of hepatic diseases

J Nanobiotechnology. 2022 Nov 19;20(1):488. doi: 10.1186/s12951-022-01708-y.

Abstract

The liver is an important organ in the human body and performs many functions, such as digestion, detoxification, metabolism, immune responses, and vitamin and mineral storage. Therefore, disorders of liver functions triggered by various hepatic diseases, including hepatitis B virus infection, nonalcoholic steatohepatitis, hepatic fibrosis, hepatocellular carcinoma, and transplant rejection, significantly threaten human health worldwide. Polymer-based nanomedicines, which can be easily engineered with ideal physicochemical characteristics and functions, have considerable merits, including contributions to improved therapeutic outcomes and reduced adverse effects of drugs, in the treatment of hepatic diseases compared to traditional therapeutic agents. This review describes liver anatomy and function, and liver targeting strategies, hepatic disease treatment applications and intrahepatic fates of polymeric nanomedicines. The challenges and outlooks of hepatic disease treatment with polymeric nanomedicines are also discussed.

Keywords: Hepatic fibrosis; Hepatitis B virus; Hepatocellular carcinoma; Host-versus-graft disease; Liver targeting; Nonalcoholic steatohepatitis; Polymeric nanomedicines.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Humans
  • Liver Neoplasms* / pathology
  • Nanomedicine
  • Polymers

Substances

  • Polymers